Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)

Inclusion Criteria: * Healthy * Parents have been informed properly regarding the study and signed the informed consent form * Parents will commit themselves to comply with the instructions of the investigator and the schedule of the trial Exclusion Criteria: * Subjects concomitantly enrolled or scheduled to be enrolled in another trial * Evolving mild, moderate, or severe illness, especially infectious diseases or fever (axillary temperature \>=37oC) * Known history of allergy to egg and/or chicken protein or any other component of the vaccines * Known history of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection * Subject who has received a treatment likely to alter the immune response in the previous 4 weeks (intravenous immunoglobulins, blood-derived products or long term corticotherapy (\>2 weeks)). * Any abnormality or chronic disease justified by investigator that might interfere assessment of the trial objectives. * Subjects has been immunized with influenza vaccine within 1 year * Subjects receives any vaccination within 1 months before and after immunization of Flubio.